DMRA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Damora Therapeutics, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 28.99 USD
0.6% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 12.5% above the Trend Line and sits at 74.0% of its 52-week range. The latest completed week returned 0.6%, after a -3.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 49 out of 100
Latest Close 28.99 USD 31 Jul 2026
1W Return 0.6% latest completed week
4W Return -3.3% short-term follow-through
12W Return 20.0% quarterly tape
Trend Breadth 71.2% 37 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 40.79% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.6% Latest completed week; four-week move -3.3%. Indicator stack 46/78 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.79% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 53/100 37 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 12.5% above the Trend Line and sits at 74.0% of its 52-week range. The latest completed week returned 0.6%, after a -3.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5112-week average 0.37

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.51Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.3% over four weeks, 20.0% over 12 weeks, and 804.5% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W0.6%
4W-3.3%
12W20.0%
26W10.5%
52W804.5%
Active trend streak2 weeks
Active weeks in one year37
Trend breadth71.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.48Latest activity-pressure read.
Pressure change240.4%Four-week change in activity pressure.
Leadership33.43Latest relative-leadership reading.
RS change-27.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-15.0%
Net share repurchases relative to market value.
Shareholder yield
-15.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 37 relevant articles.

11 positive · 25 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-24.4%Distance below the 52-week high.
13-week volatility9.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+40.6%Week of 27 Mar.
Worst week-31.1%Week of 20 Mar.
Latest week+0.6%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains8
Flat weeks0
Modest losses6
Sharp losses7
Recent vol9.5%13-week weekly-return volatility.
Base vol70.4%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew41.1% / -11.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape49/100

Trend, activity pressure, participation, and risk combine to a 49/100 tape read.

 Indicator analysis52/100

Latest 12-week confirmation: trend 5/12, activity pressure 3/12, relative leadership 12/12.

Activity pressure 0.51; No reversal markers Next-Week ExpectancyNegative 40.79%

Next-week expectancy is negative with a 40.79% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 89; Small Cap Core rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 37 relevant articles.

Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202628.99 USD0.6%25.77 USD14.28 USD0.4833.431.8MOn
24 Jul 202628.82 USD-8.4%25.53 USD14.53 USD0.4336.402.4MOn
17 Jul 202631.48 USD10.3%25.71 USD14.82 USD0.3449.922.3MOff
10 Jul 202628.53 USD-4.8%25.56 USD14.99 USD-0.0033.523.2MOff
3 Jul 202629.98 USD18.2%25.68 USD15.20 USD-0.3445.992.4MOff
26 Jun 202625.36 USD19.5%25.59 USD15.42 USD-0.6527.5910.3MOff
19 Jun 202621.23 USD2.2%25.34 USD15.66 USD-0.844.123.0MOff
12 Jun 202620.78 USD-1.1%25.19 USD15.93 USD-0.846.281.8MOff
5 Jun 202621.01 USD-15.6%25.39 USD16.26 USD-0.7311.721.9MOff
29 May 202624.88 USD-1.7%24.86 USD16.47 USD-0.6228.521.7MOn
22 May 202625.30 USD2.8%24.27 USD16.66 USD-0.6137.271.4MOn
15 May 202624.60 USD1.8%23.71 USD16.86 USD-0.6038.131.8MOn
8 May 202624.16 USD-4.7%23.21 USD17.09 USD-0.4938.312.6MOn
1 May 202625.36 USD2.5%22.83 USD17.25 USD-0.4256.64929.6KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.